{"nctId":"NCT01191086","briefTitle":"Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures","startDateStruct":{"date":"2010-10"},"conditions":["Epilepsy"],"count":210,"armGroups":[{"label":"Open-label USL255","type":"EXPERIMENTAL","interventionNames":["Drug: USL255"]}],"interventions":[{"name":"USL255","otherNames":["Topiramate extended-release"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have completed the maintenance period of the P09-004 study.\n* Continue to be treated with a stable dose of 1 to a maximum of 3 approved concomitant AEDs.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Evaluate the Safety of USL255 Through the Collection of Adverse Events and Clinical Laboratory Evaluations","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":210},"commonTop":["Weight decreased","Headache","Somnolence","Dizziness","Aphasia"]}}}